In a strategic move to streamline its focus on immunology, Bristol Myers Squibb (BMS) has joined forces with Bain Capital to establish a new biopharmaceutical entity, NewCo. This innovative venture is dedicated to advancing the development of five investigational therapies tailored to address autoimmune diseases.
With a substantial financing commitment of $300m from Bain Capital, NewCo is set to propel the progress of its preclinical and clinical portfolio, targeting key mechanisms in autoimmune conditions like interleukin pathways. Noteworthy candidates in NewCo’s pipeline include afimetoran, an oral treatment for systemic lupus erythematosus (SLE), and BMS-986322, a promising therapy for plaque psoriasis. Additionally, NewCo will oversee the development of BMS-986326, a cutting-edge IL2 fusion protein with ongoing clinical trials for atopic dermatitis and SLE.
Read more from pharmaceutical-technology.com